Mylan awarded temporary restraining order against Apotex over Paxil generic

23 July 2014

US generic drugmaker Mylan (Nasdaq: MYL) says that the US District Court for New Jersey has granted its motion for a temporary restraining order against Canadian-owned generics maker Apotex Inc and Apotex Corporation in litigation surrounding paroxetine CR, the authorized generic of GlaxoSmithKline’s(LSE: GSK) Paxil CR.

The District Court ordered that Apotex must immediately discontinue all sales and supply of SSRI antidepressant paroxetine CR, and Mylan has previously obtained an order prohibiting GSK from supplying paroxetine CR to Apotex.

Apotex was ordered to recall any product from its direct customers that had been shipped since the injunction was entered on July 16.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK